SavedAdd your journal

Journals / Tıp Araştırmaları Dergisi / 2010 / Cilt: 8 - Sayı: 3

Bladderchek test in early diagnosis and manegement of bladder tumors

Mesane tümörlerinin erken tanısında ve takibinde NMP22 bladderchek testinin yeri

ERDAL BENLİ
Güner Kemal ÖZGÜR
Pages
180–184
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Sensitivity and negative predictive values obtained from the Bladder Cancer Group makes us consider that the test mentioned above may serve as an alternative testing instrument against cystoscopy, during the follow up period of the bladder cancer and reduce the frequency of cystoscopy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We investigated the availability of the NMP22 (Nuclear Matrix Protein) Bladder Check ® 22 in the early diagnosis and follow-up of bladder cancer.
📊
Key Findings & Data:Material and Method: This study was carried out on 211 patients with hematuria or who were followed due to a diagnosis of bladder cancer, between April 2003 and September 2005.
💡
Conclusion & Impact:Sensitivity and negative predictive values obtained from the Bladder Cancer Group makes us consider that the test mentioned above may serve as an alternative testing instrument against cystoscopy, during the follow up period of the bladder cancer and reduce the frequency of cystoscopy.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: We investigated the availability of the NMP22 (Nuclear Matrix Protein) Bladder Check ® 22 in the early diagnosis and follow-up of bladder cancer. Material and Method: This study was carried out on 211 patients with hematuria or who were followed due to a diagnosis of bladder cancer, between April 2003 and September 2005. NMP22BC tumor marker and cystoscopy were compared with each other. Findings: Sensitivity, specificity, positive predictive and negative predictive values of the NMP22 BC testing were determined respectively, as 73.3%, 88.0%, 45.8% and 94.9% for the patients included in the Hematuria Group and respectively, as 100%, 96%, 77%, and 100% for the patients included in the Bladder Cancer Group. Application of the exclusion criteria in NMP22BC testing shall intensely increase efficacy. Result: We assumed that NMP22BC could be a guideline in the baseline assessment of patients with hematuria. Sensitivity and negative predictive values obtained from the Bladder Cancer Group makes us consider that the test mentioned above may serve as an alternative testing instrument against cystoscopy, during the follow up period of the bladder cancer and reduce the frequency of cystoscopy.

Özet

Amaç: Mesane kanserinin erken tanı ve takibinde Nükleer Matriks Protein 22 Bladder Chek (NMP22BC) testinin kullanılabilirliğini incelemektir. Gereç ve yöntem: Bu çalışma Nisan 2003-Eylül 2005 tarihleri arasında hematürisi olan veya mesane kanseri tanısıyla izlenen 211 hasta üzerinde gerçekleştirilmiştir. NMP22BC tümör markırı ile sistoskopi karşılaştırıldı Bulgular: Bu çalışmada NMP22BC testinin hematüri grubunda sensitivitesi %73,3; spesifitesi %88,0; pozitif prediktif değeri %45,8; negatif prediktif değeri %94,9 olarak bulunurken; mesane tümörü grubunda sensitivite %100; spesifite %96; pozitif prediktif değeri %77 ve negatif prediktif değeri %100 olarak tespit edilmiştir. NMP22BC testinde dışlama kriterleri uygulanması etkinliğini daha da arttıracaktır. Sonuç: NMP22BC testinin hematürili hastaların ilk değerlendirilmesinde yol gösterici olacağı görülmüştür. Mesane tümörlü grupta elde edilen sensitivite ve negatif prediktif değerler, testin mesane tumor takibinde sistoskopiye alternatif olabileceğini ve sistoskopi sıklığını azaltabileceğini düşündürmektedir

🔖

Cite This Article

BENLİ, E., ÖZGÜR, G. K. (2010). Bladderchek test in early diagnosis and manegement of bladder tumors. Tıp Araştırmaları Dergisi, Cilt: 8 - Sayı: 3, 180–184. https://ajindex.com/articles/361641

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Edward M. Messing, Catalona W. Urothelial tumors of the urinary tract. Campbell’s Urology. 8th Edition, USA: 2002; 2327-2383. 2. van Rhijn BW, van der poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance. Systematic Review. European Urology. 2005; 47(6): 736-748
  2. Feil G,Stenzi A. Tumor markır tests in bladder cancer. Actas Urol Esp. Jan 2006; 30(1):38-45 4. Hwa Sub Choi, Sang Ik Lee, Dong Jun Kim, Tae Yoong Jeong. Usefulness of the NMP22 BC Test for Screening and Follow-up Bladder Cancer. Korean J Urol 2010; 51: 88-93
  3. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A and Zippe C. Screenıng and monıtorıng for bladder cancer. Refining the use of NMP22. J. Urol 2001; 166: 75-78
  4. Poulakıs V, Wıtzsch U, De Vries R, Altmanssberger M, Manyak MJ and Becht E. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder. The prognostic value of false-positiv results. BJU 2001; Int. 88(7): 692-701
  5. Gutierrez C, Palou J, Bujons A,Iglesias JC, Juaneda B, Segarra J, Salvador J, Villavicencio H. The detection of nuclear matrix protein 22 in the follow up of patients after endovesical treatment with BCG. NMP22 presentations at the XIXth Congress of the Urology Vienna March 2004; 24-27
  6. Oehr P. Early detection of bladder cancer in haematüria patients. Vision becomes reality. NMP22 presentations at the XIXth Congress of the Urology March Vienna 2004; 24-27 9. Lüdecke G, Farkas R, Miller J, Weidner W. Is NMP22 a relevant tumor marker in case of primary diagnosis in bladder cancer in urological daily routine. NMP22 presentations at the XIXth Congress of the Urology 24-27 March Vienna 2004
  7. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using point of care proteomic assay. JAMA 2005; 293(7):810-816
  8. Oehr P. Non-invasive screening of urinary bladder cancer-ıs NMP22 Bladderchek paving the avenue? J. Urol 171,70,2004